ABSTRACT
Both increased dietary intake of ω-3 polyunsaturated fatty acids (PUFA) and subsequent increases in colonic mucosal ω-3 PUFA concentrations have been linked to improved gut barrier function and decreased risks of metabolic diseases and cancer. In addition, increased dietary ω-3 PUFA has been linked to eubiosis in mouse studies. Increased ω-3 PUFA function in part to reduce cyclooxygenase-(COX) mediated prostaglandin E2 (PGE2) production, a biomarker of cancer risk linked to compromised gut barrier function. We analyzed data from a dietary intervention study in individuals at increased risk of colon cancer to determine whether changes in the mucosal microbiome composition were associated with changes in colonic mucosal ω-3/ ω-6 PUFA ratio. Microbiome analyses of colonic biopsies before and after the dietary intervention from 86 participants were done by sequencing the V4 region of the 16S rRNA gene. Multivariable linear regression models were used to evaluate further whether changes in Akkermansia was associated with changes in each colonic tissue variable: ω-3/ω-6 PUFA ratios, PGE2 concentrations, and expression of COX-1 and COX-2. The median dietary intake and mucosal ω-3/ω-6 PUFA ratio increased after intervention. Greater increases in mucosal ω-3/ω-6 PUFA ratios after intervention were significantly associated with several changes in taxon abundance, including increased Akkermansia muciniphilia relative abundance. An increased abundance of Akkermansia muciniphilia also was associated significantly with decreased PGE2 concentrations but not with changes in COX expression. Further studies are warranted to elucidate mechanisms by which Akkermansia may affect or is affected by these pathways and the relative importance of individual dietary components.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
registration no. NCT00475722
Funding Statement
We acknowledge support from the University of Michigan Medical School Host Microbiome Initiative and NIH grants RO1 CA120381, Cancer Center Support Grant P30 CA046592, and the Rose and Lawrence C. Page, Sr. Family Charitable Foundation (to Dr. D. Kim Turgeon). Rena Chan was supported by the Cancer Biology Training Program grant T32 CA009676. The research used core resources supported by a Clinical Translational Science Award, NIH grant UL1RR024986 (the Michigan Clinical Research Unit), by the Michigan Diabetes Research Center, NIH grant 5P60 DK20572 (Chemistry Laboratory), the Michigan Nutrition and Obesity Research Center, and NIH grant P30 DK089503.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Michigan Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Microbiome sequences are available on SRA through NCBI.
